🔎 Trials Near Me

Início › Câncer de Ovário › Pensilvânia

Ensaios clínicos de Câncer de Ovário em Pensilvânia

69 estudos para Câncer de Ovário estão buscando participantes em locais em Pensilvânia.

Cidades em Pensilvânia

Texto oficial do estudo (Inglês)

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

  • Lehigh Valley Hospital-Cedar Crest, Allentown
  • UPMC Altoona, Altoona
  • Lehigh Valley Hospital - Muhlenberg, Bethlehem
  • e mais 18
RecrutandoFase 2
Todas as idades · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05564377

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • Abramson Cancer Center of the University of Pennsylvania, Philadelphia
  • University of Pittsburgh Medical Center, Pittsburgh
  • WellSpan York Cancer Center, York
RecrutandoFase 1/2
Idades 12 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT04585750

Distance-Based Exercise to Preserve Function and Prevent Disability

  • UPMC Hillman Cancer Center at Butler Health System, Butler
  • IRMC Cancer Center, Indiana
  • UPMC Hillman Cancer Center - New Castle, New Castle
  • e mais 2
Recrutando
Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT07059884

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

  • Sidney Kimmell Cancer Center - Jefferson Health, Philadelphia
RecrutandoFase 1
Idades 19 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT06586957

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

  • Research Site, Pittsburgh
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 29 de set. de 2026 · NCT05877599

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

  • Site 0232 - University of Pennsylvania, Philadelphia
  • Site 0178 - Thomas Jefferson University, Philadelphia
RecrutandoFase 2
Idades 18 e acima · Mulheres · Atualizado em 29 de set. de 2026 · NCT05128825

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

  • University of Pennsylvania, Philadelphia
Recrutando
Idades 18 e acima · Mulheres · Atualizado em 29 de set. de 2026 · NCT05287451

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

  • St. Lukes University Hospital /ID# 274362, Bethlehem
  • University of Pennsylvania - Perelman Center for Advanced Medicine /ID# 275612, Philadelphia
RecrutandoFase 2
Idades 18 e acima · Mulheres · Atualizado em 29 de set. de 2026 · NCT06890338

Study of AVZO-021 in Patients With Advanced Solid Tumors

  • Avenzo Therapeutics Recruiting Site, Philadelphia
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT05867251

DESTINY-PANTUMOUR04

  • Research Site, Philadelphia
RecrutandoEstudo observacional
Idades de 18 a 130 · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07124000

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

  • Perelman School of Medicine at the University of Pennsylvania, Philadelphia
RecrutandoFase 1/2
Idades 18 e acima · Mulheres · Atualizado em 24 de set. de 2026 · NCT04590326

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

  • Allegheny Health Network, Pittsburgh
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06128551

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

  • Penn Medicine University of Pennsylvania Health System /ID# 277963, Philadelphia
  • Western Pennsylvania Gynecologic Oncology /ID# 278632, Pittsburgh
RecrutandoFase 2
Idades 18 e acima · Mulheres · Atualizado em 22 de set. de 2026 · NCT07059845

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  • University of Pennsylvania Hospital, Philadelphia
  • Jefferson Health Honickman Center, Philadelphia
  • Asplundh Cancer Pavilion, Willow Grove
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07213804

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

  • University of Pennsylvania, Philadelphia
  • Fox Chase Cancer Center, Philadelphia
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07213791

Prehabilitation in High-risk Oncologic Surgery

  • Fox Chase Cancer Center - Philadelphia, Philadelphia
Recrutando
Idades 18 e acima · Todos os sexos · Atualizado em 21 de set. de 2026 · NCT07638410

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

  • University of Pennsylvania, Philadelphia
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 18 de set. de 2026 · NCT04752826

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

  • Hospital of the University of Pennsylvania ( Site 0071), Philadelphia
RecrutandoFase 3
Idades 18 e acima · Mulheres · Atualizado em 17 de set. de 2026 · NCT07318558

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  • Penn State College of Medicine, Hershey
RecrutandoFase 2
Idades de 18 a 99 · Mulheres · Atualizado em 15 de set. de 2026 · NCT07023627

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  • University of Pittsburgh Cancer Institute Cancer Services, Pittsburgh
  • Allegheny Health Network- West Penn Hospital, Pittsburgh
  • Lankenau Medical Center, Wynnewood
  • e mais 1
RecrutandoFase 3
Idades 18 e acima · Mulheres · Atualizado em 15 de set. de 2026 · NCT07214779

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

  • Allegheny Singer, Pittsburgh
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 14 de set. de 2026 · NCT06303505

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

  • St. Luke's University Health Network, Bethlehem
RecrutandoFase 3
Idades 18 e acima · Mulheres · Atualizado em 14 de set. de 2026 · NCT04575935

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

  • University of Pittsburgh Medical Center, Magee-Womens Hospital, Pittsburgh
  • West Penn Hospital of Allegheny Health Network, Pittsburgh
RecrutandoFase 2
Idades 18 e acima · Mulheres · Atualizado em 14 de set. de 2026 · NCT06787612

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

  • University of Pennsylvania, Philadelphia
  • WellSpan Medical Oncology & Hematology at York Cancer Center, York
RecrutandoEstudo observacional
Idades 18 e acima · Todos os sexos · Atualizado em 14 de set. de 2026 · NCT05059444

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

  • Research Site, Pittsburgh
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 11 de set. de 2026 · NCT05123482

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

  • Allegheny Health Network West Penn Hospital ( Site 0099), Pittsburgh
RecrutandoFase 3
Idades 18 e acima · Mulheres · Atualizado em 3 de set. de 2026 · NCT06824467

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

  • Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 2 de set. de 2026 · NCT07216105

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

  • UPMC Hillman Cancer Center, Pittsburgh
RecrutandoFase 1
Idades 15 e acima · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT06276491

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • Children's Hospital of Philadelphia, Philadelphia
  • Children's Hospital of Pittsburgh of UPMC, Pittsburgh
RecrutandoFase 1/2
12 Months – 30 Years · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT04851119

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

  • Sidney Kimmel Comprehensive Center at Jefferson, Philadelphia
  • UPMC, Pittsburgh
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 21 de ago. de 2026 · NCT06774963

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

  • Thomas Jefferson University Hospital, Philadelphia
  • UPMC Hillman Cancer Center, Pittsburgh
  • UPMC-Passavant Hospital, Pittsburgh
RecrutandoFase 2/3
Idades 18 e acima · Todos os sexos · Atualizado em 19 de ago. de 2026 · NCT07001748

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

  • Normunity Investigational Site, Philadelphia
  • Normunity Investigational Site, Philadelphia
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 18 de ago. de 2026 · NCT07182149

A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

  • SCRI - Sydney Kimmel Cancer Center - Jefferson Health, Philadelphia
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 18 de ago. de 2026 · NCT07470853

The Appendix Cancer PMP Research Foundation Natural History Study/Patient Registry

  • ACPMP, Springfield
RecrutandoEstudo observacional
Todas as idades · Todos os sexos · Atualizado em 17 de ago. de 2026 · NCT07769346

A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

  • Site 0109, Philadelphia
  • Site 0113, Philadelphia
  • Site 0114, Willow Grove
RecrutandoFase 3
Idades 18 e acima · Mulheres · Atualizado em 12 de ago. de 2026 · NCT07546500

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

  • Jefferson Abington Hospital, Abington
  • Christiana Care Health System-Concord Health Center, Chadds Ford
  • Penn State Milton S Hershey Medical Center, Hershey
  • e mais 15
Recrutando
Idades de 35 a 50 · Mulheres · Atualizado em 7 de ago. de 2026 · NCT04251052

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

  • Lehigh Valley Hospital-Cedar Crest, Allentown
  • Saint Luke's Cancer Center - Allentown, Allentown
  • Saint Luke's University Hospital-Bethlehem Campus, Bethlehem
  • e mais 21
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 7 de ago. de 2026 · NCT06580314

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

  • USOR Alliance Cancer Specialist, Doylestown
  • Allegheny Health Network, Pittsburgh
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 4 de ago. de 2026 · NCT05579366

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

  • University of Pennsylvania / Abramson Cancer Center, Philadelphia
  • Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization, Philadelphia
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 30 de jul. de 2026 · NCT04657068

Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.